NDC-11 (Package) | NDC-9 (Product) | Generic Name (Ascending) | Brand Name | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
00069-0251-60 | 00069-0251 | CRIZOTINIB | Xalkori | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, HGFR, ROS1, RON | Oral | Nov. 20, 2023 | In Use | |
00069-0507-60 | 00069-0507 | CRIZOTINIB | Xalkori | 50.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, HGFR, ROS1, RON | Oral | Nov. 20, 2023 | In Use | |
00069-1500-60 | 00069-1500 | CRIZOTINIB | Xalkori | 150.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | ALK, HGFR, ROS1, RON | Oral | Nov. 20, 2023 | In Use | |
43975-0307-10 | 43975-0307 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | March 20, 2018 | In Use | |
43975-0308-10 | 43975-0308 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | March 20, 2018 | In Use | |
54879-0021-01 | 54879-0021 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | May 8, 2018 | In Use | |
54879-0022-01 | 54879-0022 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | May 8, 2018 | In Use | |
62559-0931-01 | 62559-0931 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 50.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | June 22, 2020 | Aug. 31, 2023 | No Longer Used |
62559-0930-01 | 62559-0930 | CYCLOPHOSPHAMIDE | CYCLOPHOSPHAMIDE | 25.0 mg/1 | Chemotherapy | Alkylating Agent | Nitrogen Mustard | Oral | June 22, 2020 | March 31, 2023 | No Longer Used |
00024-5824-11 | 00024-5824 | Cabazitaxel | Jevtana | Chemotherapy | Antimitotic Agent | Taxane | Intravenous | June 17, 2010 | In Use | ||
42388-0014-25 | 42388-0014 | Cabozantinib | COMETRIQ | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov. 29, 2012 | May 31, 2016 | No Longer Used |
42388-0013-14 | 42388-0013 | Cabozantinib | COMETRIQ | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov. 29, 2012 | In Use | |
42388-0023-26 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | April 25, 2016 | In Use | |
42388-0023-36 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Nov. 16, 2017 | In Use | |
42388-0023-37 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Oct. 3, 2018 | In Use | |
42388-0023-46 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
42388-0023-57 | 42388-0023 | Cabozantinib | CABOMETYX | 60.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
42388-0024-26 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | April 25, 2016 | In Use | |
42388-0024-37 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb. 27, 2019 | In Use | |
42388-0024-46 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
42388-0024-57 | 42388-0024 | Cabozantinib | CABOMETYX | 20.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
42388-0025-26 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | April 25, 2016 | In Use | |
42388-0025-37 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Feb. 27, 2019 | In Use | |
42388-0025-46 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use | |
42388-0025-57 | 42388-0025 | Cabozantinib | CABOMETYX | 40.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 9, 2023 | In Use |
Found 10,000 results in 4 milliseconds — Export these results